IP Verse

Nant competitive analysis

Loading summary...

Latest oppositions filed by Nant

Explore patent oppositions filed by Nant against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 6, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3570885
Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)AMGENJun 16, 2025
EP3684786
Mutated Glycoprotein Of Vesicular Stomatitis VirusCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSMay 14, 2025
EP3506931
Methods For Preventing Or Treating Allergy By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSApr 30, 2025
EP3889181
Methods For Treating Atopic Dermatitis By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJan 24, 2025
EP3820625
Device For Dispensing A Fluid Product, And Method For Filling And For Plugging SameAPTAR FRANCEDec 12, 2024
EP3818078
Methods Of Producing Recombinant ProteinsBRISTOL MYERS SQUIBBNov 26, 2024
EP3585402
Compositions, Articles Of Manufacture And Methods Related To Dosing In Cell TherapyJUNO THERAPEUTICSNov 12, 2024
EP3515465
Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALSNov 6, 2024
EP3973987
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSOct 10, 2024
EP3703818
Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJul 30, 2024

Latest patents of Nant opposed by its competitors

Explore Nant's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 6, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3059307
May 4, 2022Use Of A Laminin For Differentiating Pluripotent Cells Into Hepatocyte Lineage Cells1
EP3256573
Dec 9, 2020Recombinant Adeno-Associated Virus Particle Purification With Multiple-Step Anion Exchange Chromatography1
EP3256574
Nov 25, 2020Recombinant Adeno-Associated Virus Particle Purification Comprising An Affinity Purification Step7

Latest PTAB cases involving Nant

Discover the latest PTAB cases involving Nant, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 9, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Nant

IPR2021-01387Aug 27, 2021BANK OF AMERICANANTTerminated-Settled
IPR2021-01388Aug 26, 2021BANK OF AMERICANANTInstitution Denied
IPR2021-01389Aug 22, 2021BANK OF AMERICANANTInstitution Denied
IPR2021-01332Aug 8, 2021BANK OF AMERICANANTFinal Written Decision
IPR2021-01333Aug 6, 2021BANK OF AMERICANANTFinal Written Decision
IPR2021-01304Jul 24, 2021BANK OF AMERICANANTFinal Written Decision
IPR2021-01081Jun 21, 2021BANK OF AMERICA NANANTFinal Written Decision
IPR2021-01080Jun 16, 2021BANK OF AMERICA NANANTTerminated-Settled
IPR2021-01133Jun 15, 2021NIANTICNANTInstitution Denied
IPR2021-01119Jun 14, 2021NIANTICNANTInstitution Denied

Peer Comparison New

IP litigation analysis comparing Nant with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 6, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BOULT WADE TENNANT52 - - -
DANA FARBER CANCER INSTITUTE - 1431
REGENERON PHARMACEUTICALS3894931
SANOFI BIOTECHNOLOGY - 51 - -